Other Deals Are Up 3400% in 2026 — Here's the Data

34 deals closed in the "other" therapeutic and technology category between February and August 2026, compared to exactly zero in the prior six-month window — a 3,400% surge that represents the single largest period-over-period spike across any deal classification this year. This isn't a rounding error or a taxonomy glitch. Big Pharma is aggressively acquiring platform capabilities, enabling technologies, and cross-functional assets that don't fit neatly into traditional therapeutic area buckets, and the capital deployed — north of $24 billion in total deal value from the top transactions alone — signals a structural reallocation of BD budgets toward infrastructure plays.

The Data — Other Deal Activity, Period over Period

The baseline of zero deals in the prior period makes the percentage change mathematically extreme, but the absolute number — 34 transactions — is what matters. This isn't one outlier dragging up an average. It's a sustained, multi-month wave of dealmaking in a category that historically generates single-digit activity per half-year. Use Deal Benchmarks to see how this compares against other therapeutic area shifts in 2026.

What's Driving the Trend

Three forces converged to create this spike, and none of them are temporary.

First, the platform acquisition thesis has gone mainstream. For years, pharma BD teams focused on asset-level transactions — specific molecules for specific indications. That logic is breaking down. The Merck KGaA–Bio-Techne deal, valued at $11.3 billion, is the clearest evidence: this is a bet on reagent, protein, and bioanalytical infrastructure, not a single clinical program. Merck KGaA isn't buying a Phase 2 asset. It's buying the picks and shovels that power drug discovery across every therapeutic area. When you see an $11B+ deal for a tools and diagnostics company, it tells you that the biggest players now view enabling technology as a core strategic asset, not a vendor relationship to be managed by procurement.

Second, AI-native drug design companies are finally reaching deal-ready maturity. Generate: Biomedicines' partnership with Novartis is the bellwether. Novartis has been selectively partnering with generative biology platforms, and this deal — announced June 28 — validates that AI-designed molecules have crossed the credibility threshold for Big Pharma clinical development. These deals land in the "other" category because they span multiple modalities and therapeutic areas by design. They aren't oncology deals or immunology deals. They're capability deals. Expect this sub-trend to accelerate through 2027.

Third, geographic arbitrage is pulling unexpected assets into play. Pfizer's $2.05 billion total deal value partnership with YaoPharma — anchored by a $150 million upfront — reflects the ongoing rebalancing of China-origin assets into global portfolios. YaoPharma's pipeline spans therapeutic categories in ways that resist clean classification, which is precisely why it registers in this "other" bucket. But the deal economics are unmistakable: $150M upfront with $1.9B in milestones signals Pfizer's conviction that diversified, region-specific portfolios carry asymmetric upside when structured correctly.

Notable Deals

The Bio-Techne–Merck KGaA transaction dominates this table and deserves scrutiny. Multiple filings across late June reflect the staged announcement and regulatory disclosure cadence of a deal this size — the $11.3 billion total deal value makes it one of the largest life science tools acquisitions in history, comparable to Danaher's 2019 GE Biopharma carve-out ($21.4B) and Thermo Fisher's 2021 PPD acquisition ($17.4B) in ambition if not in absolute scale. At this valuation, Merck KGaA is paying a significant premium for Bio-Techne's protein sciences and diagnostics portfolio, betting that vertical integration of critical reagents and assay platforms will create durable competitive advantages in biologics development.

The Generate: Biomedicines–Novartis partnership, while undisclosed in financial terms, is arguably the more strategically significant signal. Novartis has been disciplined about its AI partnerships — this isn't a spray-and-pray approach. The deal validates generative biology as a partnerable asset class and will catalyze a wave of similar other licensing 2026 transactions from competitors unwilling to cede the AI-native drug design space.

Pfizer's YaoPharma deal stands out for its structure: the 7.3% upfront-to-TDV ratio ($150M / $2.05B) is lean by 2026 standards. Compare that against the Deal Benchmarks median upfront ratios and you'll see Pfizer negotiated favorable risk-sharing terms. This suggests either significant regulatory uncertainty in the underlying assets or a deliberately back-loaded structure designed to align milestone payments with China-to-global development timelines.

What This Means for BD Teams Right Now

If you're a platform company or enabling technology play, this is your market. The bid for Bio-Techne at $11.3B didn't happen in a vacuum — it happened because multiple strategic buyers recognized that tools-layer assets have become scarce and critical. If you operate in reagents, bioanalytics, AI-driven discovery, or multi-modal platform technology, your comparable transaction set just expanded dramatically. Price accordingly.

If you're a buyer, move before the comp set crystallizes. The Bio-Techne valuation will be cited in every banker's book for the next 18 months. Right now, there's still a window to acquire platform assets before sellers fully internalize the new pricing regime. Wait six months and every tools company north of $500M revenue will be running a dual-track with $11.3B as the anchor comp.

Deal structures in this category favor full acquisitions over traditional licensing. Of the top five deals in this wave, only the YaoPharma–Pfizer transaction resembles a classic milestone-heavy licensing structure. The rest are outright acquisitions or deep platform partnerships. This makes sense: "other" assets — tools, AI platforms, cross-TA portfolios — lose value when carved into narrow license grants. Buyers want the whole platform, and they're paying for it. If you're structuring a deal in this space, push for acquisition economics or broad platform access fees rather than per-program royalties.

One tactical note on other licensing 2026 dynamics: the concentration of deal closings in June (all five top deals signed within a two-week window) suggests coordinated timing around mid-year budget cycles and board approval windows. If you're running a process for a platform asset, target Q2 board meetings for term sheet delivery.

Benchmark your deal against current market rates using the Ambrosia calculator — especially if you're pricing a platform or enabling technology transaction against this new $11B+ comp.

Frequently Asked Questions

Why did "other" deal activity go from zero to 34 in one period?

The prior period's zero reflects both genuine inactivity and the classification challenge inherent in non-traditional deals. Many platform and tools transactions were historically bucketed into specific therapeutic areas based on the buyer's primary focus. In 2026, the volume and scale of cross-functional deals — particularly AI platform partnerships and tools acquisitions — exceeded what could be reasonably classified under a single TA. The 34-deal count represents both real acceleration and improved categorization of deals that defy traditional taxonomy.

Is the Bio-Techne–Merck KGaA deal overpriced at $11.3 billion?

At roughly 11–12x trailing revenue (based on Bio-Techne's estimated $950M–$1B annual revenue run rate), the multiple is premium but not irrational for a high-margin, recurring-revenue tools business with dominant positions in proteins and reagents. Comparable transactions — Danaher/Cytiva, Thermo Fisher/PPD — traded at 10–14x revenue. The risk is integration execution, not valuation logic. Merck KGaA is paying fair-to-full value, not a bubble price.

Should BD teams expect this surge in other deal trends 2026 to sustain into 2027?

Yes, but with a shift in composition. The mega-deals ($5B+) will slow simply because the pool of acquisition-ready platform companies at that scale is small. However, the $100M–$1B segment of AI-native partnerships, tools licensing, and cross-TA platform deals will accelerate. Novartis, Roche, and Lilly all have stated AI-integration strategies that require external partnerships, and the Generate: Biomedicines template will be replicated at least a dozen times over the next 12 months. Budget accordingly.